AU Patent

AU2013352406A1 — Combination therapy

Assigned to Novartis AG · Expires 2015-06-04 · 11y expired

What this patent protects

The present invention relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof and (2) a second agent which is a mTOR inhibitor or a pharmaceutically acceptable salt thereof.

USPTO Abstract

The present invention relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof and (2) a second agent which is a mTOR inhibitor or a pharmaceutically acceptable salt thereof.

Drugs covered by this patent

elacestrant-hydrochloride (ELACESTRANT HYDROCHLORIDE)

Patent Metadata

Patent number: AU2013352406A1
Jurisdiction: AU
Classification: —
Expires: 2015-06-04
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.